Acta Materia Medica (Feb 2022)

Advances in therapeutic agents targeting quiescent cancer cells

  • Wan Najbah Nik Nabil,
  • Zhichao Xi,
  • Mengfan Liu,
  • Yang Li,
  • Mu Yao,
  • Tao Liu,
  • Qihan Dong,
  • Hongxi Xu

DOI
https://doi.org/10.15212/AMM-2021-0005
Journal volume & issue
Vol. 1, no. 1
pp. 56 – 71

Abstract

Read online

Quiescent cancer cells (QCCs) reversibly reside in G0 phase, thus allowing them to survive chemotherapy and radiotherapy, which generally target proliferating cells. Surviving QCCs may re-proliferate, and consequently result in cancer progression, recurrence, and metastasis. Therefore, understanding the key players governing QCC survival and activation is crucial for developing QCC-targeting agents. This review presents an overview of (1) the mechanisms underlying the regulation of QCC status and (2) recent advances in the development of QCC-targeting therapeutic agents and their underlying mechanisms. The development of effective therapeutic modalities that target QCCs may enable new cancer treatments to prevent cancer progression and recurrence.

Keywords